

Serial No.:

Filed:



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

application of: David BEACH et al.

09/016,869

January 30, 1998

For: Cell-Cycle Regulatory Proteins, and Uses Related Thereto

Atty Docket: MIV-071.10

Group Art Unit: 1644

Examiner: M. Tung

CERTIFICATE MAILING UNDER 37 C.F.R. §1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail, postage prepaid, in an envelope addressed to: Assistant Commissioner for Patents Washington, D.C. 20231 dated June 1, 2000.

June 1, 2000

Date of Signature and of Mail Deposit

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

EI

RESPONSE TO NOTICE TO COMPLY

TECH CENTER 1800/2860

In response to the Notice to Comply dated May 4, 2000, Applicants submit herewith a hard copy of the sequence listing and a computer readable form of the sequence listing (the diskette).

Please replace pages 65-87 of the specification with the amended sequence listing on the replacement pages enclosed herewith (pages 65-87).

I hereby state that the content of the Sequence Listing and the computer-readable copies of the Sequence Listing submitted in accordance with 37 C.F.R. § 1.821(c) and (e), respectively, are the same. I further state that this submission, filed in accordance with 37 C.F.R. § 1.821(g), does not include new matter.





Any questions arising from this submission may be directed to the undersigned. If there are any fees due in connection with the filing of this Response, please charge the fees to our **Deposit Account No. 06-1448.** If a fee is required for an extension of time under 37 C.F.R. § 1.136 not accounted for above, such an extension is requested and the fee should also be charged to our Deposit account.

Respectfully submitted, FOLEY, HOAG, & ELIOT

David P. Halstead, Ph.D.


Reg. No. 44,735

Agent for Applicants

Dated: June 1, 2000

Patent Group Foley, Hoag & Eliot LLP One Post Office Square Boston, MA 02109-2170 Tel: (617) 832-1000

FAX: (617) 832-7000



DEPARTMENT OF COMMERC

Patent and Trad mark Office

COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

APPLICATION NO. FIRST NAMED INVENTOR FILING DATE ATTORNEY DOCKET NO

09/016,869

01/30/98

BEACH

D MIV-071.10

EXAMINER

HM22/0504

TUNG, M

PATENT GROUP FOLEY HOAG & ELIOT ONE POST OFFICE SQUARE BOSTON MA 02109-2170

1644

ART UNIT

PAPER NUMBER

DATE MAILED:

05/04/00


Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

RECEIVED

MAY 08 2000

PATENT DEPT DOCKETING



UNITED DES DEPARTMENT OF COMMERCE Patent and Trademark Office COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

SERIAL NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO.
09/016,869	1/30/98	Beach, et al.	071.10

EXAMINER

Mary Tung

ART UNIT PAPER NUMBER

1644 14

DATE MAILED:

Please find below a communication from the EXAMINER in charge of this application

Commissioner of Patents

The reply filed 3/23/2000 is not fully responsive to the communication mailed 12/14/99 for the reason(s) set forth on the attached Notice To Comply With The Sequence Rules and CRF Diskette Problem Report.

Since the above-mentioned reply appears to be *bona fide*, applicant is given a TIME PERIOD of **ONE (1) MONTH** or **THIRTY (30) DAYS**, from the mailing date of this notice, whichever is longer, within which to supply the omission or correction in order to avoid abandonment. EXTENSIONS OF THIS TIME LIMIT MAY BE GRANTED UNDER 37 CFR 1.136(a).

Any inquiry concerning this communication should be directed to Examiner Mary Tung, Art Unit 1644, whose telephone number is (703) 308-9344.

Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist whose telephone number is (703) 308-0196.

Mary B. Tung, Ph.D. Patent Examiner

Art Unit 1644

May 3, 2000

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

	 This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
	2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
	3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
X	4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37,C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
	5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
	6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
П	7. Other:
Ap	plicant Must Provide:
X	An initial or <u>substitute</u> computer readable form (CRF) copy of the "Sequence Listing".
X	An initial or <u>substitute</u> paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
X	A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).
Fo	r questions regarding compliance to these requirements, please contact:
Fo	r Rules Interpretation, call (703) 308-4216 r CRF Submission Help, call (703) 308-4212 tentIn Software Program Support (SIRA) Technical Assistance
	To Purchase Patentin Software

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE